Labcorp Holdings Inc. $LH Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC grew its stake in shares of Labcorp Holdings Inc. (NYSE:LH) by 225.5% during the fourth quarter, Holdings Channel reports. The firm owned 68,082 shares of the medical research company’s stock after purchasing an additional 47,165 shares during the period. SG Americas Securities LLC’s holdings in Labcorp were worth $17,080,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of LH. HBK Sorce Advisory LLC increased its stake in Labcorp by 4.3% during the 3rd quarter. HBK Sorce Advisory LLC now owns 916 shares of the medical research company’s stock valued at $254,000 after buying an additional 38 shares during the period. Pure Financial Advisors LLC lifted its stake in shares of Labcorp by 3.9% in the 3rd quarter. Pure Financial Advisors LLC now owns 1,017 shares of the medical research company’s stock worth $292,000 after acquiring an additional 38 shares during the period. Hantz Financial Services Inc. lifted its stake in shares of Labcorp by 48.8% in the 3rd quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company’s stock worth $35,000 after acquiring an additional 40 shares during the period. Burney Co. boosted its holdings in shares of Labcorp by 0.5% in the third quarter. Burney Co. now owns 8,819 shares of the medical research company’s stock valued at $2,532,000 after acquiring an additional 42 shares in the last quarter. Finally, Advisor OS LLC increased its stake in shares of Labcorp by 5.4% during the third quarter. Advisor OS LLC now owns 821 shares of the medical research company’s stock valued at $236,000 after acquiring an additional 42 shares during the period. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Insider Buying and Selling

In other Labcorp news, EVP Der Vaart Sandra D. Van sold 548 shares of the business’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $284.91, for a total transaction of $156,130.68. Following the sale, the executive vice president owned 2,579 shares in the company, valued at approximately $734,782.89. The trade was a 17.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Adam H. Schechter sold 8,705 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $279.96, for a total transaction of $2,437,051.80. Following the sale, the chief executive officer directly owned 80,773 shares of the company’s stock, valued at $22,613,209.08. This represents a 9.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 16,113 shares of company stock valued at $4,547,450. 0.84% of the stock is currently owned by company insiders.

Labcorp Trading Down 1.4%

Shares of NYSE:LH opened at $264.52 on Friday. The stock has a market capitalization of $21.80 billion, a price-to-earnings ratio of 25.29, a PEG ratio of 1.83 and a beta of 1.01. Labcorp Holdings Inc. has a 1-year low of $209.38 and a 1-year high of $293.72. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.23 and a current ratio of 1.42. The company has a 50 day moving average price of $274.20 and a 200 day moving average price of $269.23.

Labcorp (NYSE:LH) last posted its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.95 by $0.12. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The company had revenue of $3.52 billion for the quarter, compared to analysts’ expectations of $3.56 billion. During the same quarter in the prior year, the company earned $3.45 earnings per share. The firm’s revenue was up 5.6% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. On average, research analysts anticipate that Labcorp Holdings Inc. will post 16.01 EPS for the current fiscal year.

Labcorp Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 12th. Stockholders of record on Friday, February 27th were given a dividend of $0.72 per share. The ex-dividend date of this dividend was Friday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. Labcorp’s payout ratio is 27.53%.

Analysts Set New Price Targets

Several equities research analysts recently commented on LH shares. Robert W. Baird boosted their target price on Labcorp from $313.00 to $326.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Weiss Ratings raised Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, February 10th. Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Piper Sandler boosted their price objective on Labcorp from $270.00 to $300.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 24th. Finally, Morgan Stanley restated an “overweight” rating on shares of Labcorp in a report on Tuesday, February 17th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Labcorp has a consensus rating of “Moderate Buy” and an average target price of $304.82.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.